A first‐in‐human, randomized study of the safety, pharmacokinetics and pharmacodynamics of povetacicept, an enhanced dual BAFF/APRIL antagonist, in healthy adults

A first‐in‐human, randomized study of the safety, pharmacokinetics and pharmacodynamics of povetacicept, an enhanced dual BAFF/APRIL antagonist, in healthy adults

Abstract Therapeutic agents targeting the tumor necrosis factor (TNF) superfamily cytokines B‐cell activating factor (BAFF, BLyS) and/or A PRoliferation Inducing Ligand (APRIL) have demonstrated clinical effectiveness in multiple autoimmune diseases, such as systemic lupus erythematosus, lupus nephr...

Full description

Saved in:
Bibliographic Details
Main Authors: Rupert Davies, Stanford L. Peng, Jason Lickliter, Kristi McLendon, Amanda Enstrom, Allison G. Chunyk, Lori Blanchfield, NingXin Wang, Tiffany Blair, Heather M. Thomas, Alina Smith, Stacey R. Dillon
Format: Article
Language:English
Published: Wiley 2024-11-01
Series:Clinical and Translational Science
Online Access:https://doi.org/10.1111/cts.70055
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1111/cts.70055

Similar Items